These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 12452739

  • 1. Pharmacokinetics and pharmacodynamics of glyburide/metformin tablets (Glucovance) versus equivalent doses of glyburide and metformin in patients with type 2 diabetes.
    Donahue SR, Turner KC, Patel S.
    Clin Pharmacokinet; 2002; 41(15):1301-9. PubMed ID: 12452739
    [Abstract] [Full Text] [Related]

  • 2. Beta-cell response to metformin-glibenclamide combination tablets (Glucovance) in patients with type 2 diabetes.
    Bruce S, Park JS, Fiedorek FT, Howlett HC.
    Int J Clin Pract; 2006 Jul; 60(7):783-90. PubMed ID: 16846398
    [Abstract] [Full Text] [Related]

  • 3. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL, Figgitt DP.
    Pharmacoeconomics; 2004 Jul; 22(6):389-411. PubMed ID: 15099124
    [Abstract] [Full Text] [Related]

  • 4. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.
    Wang JS, Lin SD, Lee WJ, Su SL, Lee IT, Tu ST, Tseng YH, Lin SY, Sheu WH.
    Clin Ther; 2011 Dec; 33(12):1932-42. PubMed ID: 22078152
    [Abstract] [Full Text] [Related]

  • 5. Improved glycaemic control with metformin-glibenclamide combined tablet therapy (Glucovance) in Type 2 diabetic patients inadequately controlled on metformin.
    Marre M, Howlett H, Lehert P, Allavoine T.
    Diabet Med; 2002 Aug; 19(8):673-80. PubMed ID: 12147149
    [Abstract] [Full Text] [Related]

  • 6. Glyburide/metformin tablets: a new therapeutic option for the management of Type 2 diabetes.
    Dailey GE.
    Expert Opin Pharmacother; 2003 Aug; 4(8):1417-30. PubMed ID: 12877648
    [Abstract] [Full Text] [Related]

  • 7. Metformin-glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy.
    Garber A, Klein E, Bruce S, Sankoh S, Mohideen P.
    Diabetes Obes Metab; 2006 Mar; 8(2):156-63. PubMed ID: 16448519
    [Abstract] [Full Text] [Related]

  • 8. A comparison of preconstituted, fixed combinations of low-dose glyburide plus metformin versus high-dose glyburide alone in the treatment of type 2 diabetic patients.
    Erle G, Lovise S, Stocchiero C, Lora L, Coppini A, Marchetti P, Merante D.
    Acta Diabetol; 1999 Jun; 36(1-2):61-5. PubMed ID: 10436254
    [Abstract] [Full Text] [Related]

  • 9. Tolerability profile of metformin/glibenclamide combination tablets (Glucovance): a new treatment for the management of type 2 diabetes mellitus.
    Davidson JA, Scheen AJ, Howlett HC.
    Drug Saf; 2004 Jun; 27(15):1205-16. PubMed ID: 15588116
    [Abstract] [Full Text] [Related]

  • 10. Effects of two different glibenclamide dose-strengths in the fixed combination with metformin in patients with poorly controlled T2DM: a double blind, prospective, randomised, cross-over clinical trial.
    Brunetti P, Pagano G, Turco C, Gori M, Perriello G, Glibo 5 Study Group.
    Diabetes Nutr Metab; 2004 Dec; 17(6):350-7. PubMed ID: 15887629
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of glyburide/metformin tablets compared with initial monotherapy in type 2 diabetes.
    Garber AJ, Donovan DS, Dandona P, Bruce S, Park JS.
    J Clin Endocrinol Metab; 2003 Aug; 88(8):3598-604. PubMed ID: 12915642
    [Abstract] [Full Text] [Related]

  • 12. Durability of efficacy and long-term safety profile of glyburide/metformin tablets in patients with type 2 diabetes mellitus: an open-label extension study.
    Garber AJ, Bruce S, Fiedorek FT.
    Clin Ther; 2002 Sep; 24(9):1401-13. PubMed ID: 12380632
    [Abstract] [Full Text] [Related]

  • 13. Improvements in glycemic control in type 2 diabetes patients switched from sulfonylurea coadministered with metformin to glyburide-metformin tablets.
    Duckworth W, Marcelli M, Padden M, Kellick K, Duhancik T, Wilhardt M, Colgan K, Romie A.
    J Manag Care Pharm; 2003 Sep; 9(3):256-62. PubMed ID: 14613469
    [Abstract] [Full Text] [Related]

  • 14. Influence of initial hyperglycaemia, weight and age on the blood glucose lowering efficacy and incidence of hypoglycaemic symptoms with a single-tablet metformin-glibenclamide therapy (Glucovance) in type 2 diabetes.
    Garber A, Marre M, Blonde L, Allavoine T, Howlett H, Lehert P, Cornes M.
    Diabetes Obes Metab; 2003 May; 5(3):171-9. PubMed ID: 12681024
    [Abstract] [Full Text] [Related]

  • 15. Simultaneous glyburide/metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes.
    Garber AJ, Larsen J, Schneider SH, Piper BA, Henry D, Glyburide/Metformin Initial Therapy Study Group.
    Diabetes Obes Metab; 2002 May; 4(3):201-8. PubMed ID: 12047399
    [Abstract] [Full Text] [Related]

  • 16. Durable efficacy of metformin/glibenclamide combination tablets (Glucovance) during 52 weeks of open-label treatment in type 2 diabetic patients with hyperglycaemia despite previous sulphonylurea monotherapy.
    Blonde L, Joyal S, Henry D, Howlett H.
    Int J Clin Pract; 2004 Sep; 58(9):820-6. PubMed ID: 15529514
    [Abstract] [Full Text] [Related]

  • 17. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.
    Tîrgovişte CI, Străchinariu R, Farcaşiu E, Milicevic Z, Teodorescu G.
    Rom J Intern Med; 2003 Sep; 41(2):153-62. PubMed ID: 15526500
    [Abstract] [Full Text] [Related]

  • 18. [Formulation by design of experiments of immediate release tablets with metformin hydrochloride and glibenclamide].
    Potur RG, Gafiţanu E.
    Rev Med Chir Soc Med Nat Iasi; 2010 Sep; 114(4):1219-26. PubMed ID: 21500483
    [Abstract] [Full Text] [Related]

  • 19. Lipid effects of glyburide/metformin tablets in patients with type 2 diabetes mellitus with poor glycemic control and dyslipidemia in an open-label extension study.
    Dailey GE, Mohideen P, Fiedorek FT.
    Clin Ther; 2002 Sep; 24(9):1426-38. PubMed ID: 12380634
    [Abstract] [Full Text] [Related]

  • 20. The development of an oral antidiabetic combination tablet: design, evaluation and clinical benefits for patients with type 2 diabetes.
    Howlett H, Porte F, Allavoine T, Kuhn T, Nicholson G.
    Curr Med Res Opin; 2003 Sep; 19(3):218-25. PubMed ID: 12803736
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.